Research ArticleOriginal Article

Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets

Huanyu Zhao, Ruoyu Dang, Yipan Zhu, Baijian Qu, Yasra Sayyed, Ying Wen, Xicheng Liu, Jianping Lin and Luyuan Li
Cancer Biology & Medicine September 2022, 19 (9) 1352-1374; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0586

References

  1. 1.↵
    2. Sung H,
    3. Ferlay J,
    4. Siegel RL,
    5. Laversanne M,
    6. Soerjomataram I,
    7. Jemal A, et al.
    Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Harbeck N,
    3. Gnant M.
    Breast cancer. Lancet. 2017; 389: 1134–50.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Ren Z,
    3. Lv M,
    4. Yu Q,
    5. Bao J,
    6. Lou K,
    7. Li X.
    MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/Nf-κB axis to promote breast cancer progression. FASEB J. 2021; 35: e21383.
  4. 4.↵
    2. Cavallo F,
    3. De Giovanni C,
    4. Nanni P,
    5. Forni G,
    6. Lollini PL.
    2011: the immune hallmarks of cancer. Cancer Immunol Immunother. 2011; 60: 319–26.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Tower H,
    3. Ruppert M,
    4. Britt K.
    The immune microenvironment of breast cancer progression. Cancers. 2019; 11: 1375.
    OpenUrlCrossRef
  6. 6.↵
    Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61–70.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Curtis C,
    3. Shah SP,
    4. Chin SF,
    5. Turashvili G,
    6. Rueda OM,
    7. Dunning MJ, et al.
    The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486: 346–52.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Xie Y,
    3. Davis Lynn BC,
    4. Moir N,
    5. Cameron DA,
    6. Figueroa JD,
    7. Sims AH.
    Breast cancer gene expression datasets do not reflect the disease at the population level. NPJ Breast Cancer. 2020; 6: 39.
    OpenUrl
  9. 9.↵
    2. Jin H,
    3. Huang X,
    4. Shao K,
    5. Li G,
    6. Wang J,
    7. Yang H, et al.
    Integrated bioinformatics analysis to identify 15 hub genes in breast cancer. Oncol Lett. 2019; 18: 1023–34.
    OpenUrl
  10. 10.↵
    2. Hao M,
    3. Liu W,
    4. Ding C,
    5. Peng X,
    6. Zhang Y,
    7. Chen H, et al.
    Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis. PeerJ. 2020; 8: e9946.
  11. 11.↵
    2. Clare SE,
    3. Shaw PL.
    “Big data” for breast cancer: Where to look and what you will find. NPJ Breast Cancer. 2016; 2: 16031.
  12. 12.↵
    2. Kolde R,
    3. Laur S,
    4. Adler P,
    5. Vilo J.
    Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012; 28: 573–80.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Tarazona S,
    3. Furió-Tarí P,
    4. Turrà D,
    5. Pietro AD,
    6. Nueda MJ,
    7. Ferrer A, et al.
    Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. Nucleic Acids Res. 2015; 43: e140.
  14. 14.↵
    2. Goldman MJ,
    3. Craft B,
    4. Hastie M,
    5. Repečka K,
    6. McDade F,
    7. Kamath A, et al.
    Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38: 675–8.
    OpenUrlPubMed
  15. 15.↵
    2. Shannon P,
    3. Markiel A,
    4. Ozier O,
    5. Baliga NS,
    6. Wang JT,
    7. Ramage D, et al.
    Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13: 2498–504.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Hänzelmann S,
    3. Castelo R,
    4. Guinney J.
    GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Newman AM,
    3. Liu CL,
    4. Green MR,
    5. Gentles AJ,
    6. Feng W,
    7. Xu Y, et al.
    Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12: 453–7.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Li T,
    3. Fu J,
    4. Zeng Z,
    5. Cohen D,
    6. Li J,
    7. Chen Q, et al.
    TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48: W509-14.
  19. 19.↵
    2. Guan X,
    3. Xu ZY,
    4. Chen R,
    5. Qin JJ,
    6. Cheng XD.
    Identification of an immune gene-associated prognostic signature and its association with a poor prognosis in gastric cancer patients. Front Oncol. 2020; 10: 629909.
  20. 20.↵
    2. Stupnikov A,
    3. McInerney CE,
    4. Savage KI,
    5. McIntosh SA,
    6. Emmert-Streib F,
    7. Kennedy R, et al.
    Robustness of differential gene expression analysis of RNA-seq. Comput Struct Biotechnol J. 2021; 19: 3470–81.
    OpenUrlCrossRef
  21. 21.↵
    2. Wu D,
    3. Pan Y,
    4. Zheng X.
    Identification of hub genes-based predictive model in hepatocellular carcinoma by robust rank aggregation and regression analysis. J Cancer. 2021; 12: 1884–93.
    OpenUrl
  22. 22.↵
    2. Thul PJ,
    3. Lindskog C.
    The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018; 27: 233–44.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Haynes WA,
    3. Vallania F,
    4. Liu C,
    5. Bongen E,
    6. Tomczak A,
    7. Andres-Terrè M, et al.
    Empowering multi-cohort gene expression analysis to increase reproducibility. Pac Symp Biocomput. 2017; 22: 144–53.
    OpenUrlCrossRef
  24. 24.
    2. Lofgren S,
    3. Hinchcliff M,
    4. Carns M,
    5. Wood T,
    6. Aren K,
    7. Arroyo E, et al.
    Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. JCI insight. 2016; 1: e89073.
  25. 25.↵
    2. Sweeney TE,
    3. Haynes WA,
    4. Vallania F,
    5. Ioannidis JP,
    6. Khatri P.
    Methods to increase reproducibility in differential gene expression via meta-analysis. Nucleic Acids Res. 2017; 45: e1.
  26. 26.↵
    2. House IG,
    3. Savas P,
    4. Lai J,
    5. Chen AXY,
    6. Oliver AJ,
    7. Teo ZL, et al.
    Macrophage-derived cxcl9 and cxcl10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020; 26: 487–504.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Liang YK,
    3. Deng ZK,
    4. Chen MT,
    5. Qiu SQ,
    6. Xiao YS,
    7. Qi YZ, et al.
    CXCL9 is a potential biomarker of immune infiltration associated with favorable prognosis in er-negative breast cancer. Front Oncol. 2021; 11: 710286.
  28. 28.↵
    2. Chen L,
    3. Zeng T,
    4. Pan X,
    5. Zhang YH,
    6. Huang T,
    7. Cai YD.
    Identifying methylation pattern and genes associated with breast cancer subtypes. Int J Mol Sci. 2019; 20: 4269.
    OpenUrl
  29. 29.↵
    2. Pan X,
    3. Hu X,
    4. Zhang YH,
    5. Chen L,
    6. Zhu L,
    7. Wan S, et al.
    Identification of the copy number variant biomarkers for breast cancer subtypes. Mol Genet Genomics. 2019; 294: 95–110.
    OpenUrlCrossRef
  30. 30.↵
    2. Schilder BM,
    3. Navarro E,
    4. Raj T.
    Multi-omic insights into parkinson‘s disease: from genetic associations to functional mechanisms. Neurobiol Dis. 2022; 163: 105580.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords